U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H26N2O2
Molecular Weight 326.4326
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HYDROQUINIDINE

SMILES

CC[C@H]1C[N@@]2CC[C@H]1C[C@@H]2[C@@H](O)C3=C4C=C(OC)C=CC4=NC=C3

InChI

InChIKey=LJOQGZACKSYWCH-LHHVKLHASA-N
InChI=1S/C20H26N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h4-6,8,11,13-14,19-20,23H,3,7,9-10,12H2,1-2H3/t13-,14-,19+,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula C20H26N2O2
Molecular Weight 326.4326
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24068450 http://www.ajtmh.org/content/s1-12/6/473.full.pdf

Hydroquinidine is a pharmaceutical agent that acts as a class I antiarrhythmic agent (Ia) in the heart. Hydroquinidine is a d-rotatory alkaloid derived from cinchiona bark. It is closely related to quinidine, differing from the latter alkaloid only in containing two more atoms of hydrogen in the molecule. The drug causes increased action potential duration, as well as a prolonged QT interval. It is not approved by FDA, but marketed in Spain, France, Italy and Pakistan under the brand names Lentoquine, Sérécor LP, Idrochinidina Lirca and Austacute, respectively. Like all other class I antiarrhythmic agents, Hydroquinidine primarily works by blocking the fast inward sodium current (INa). Hydroquinidine is also used for the treatment of Malaria.

Approval Year

Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.74 mg/L
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROQUINIDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.55 mg/L
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
HYDROQUINIDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10.8 h
300 mg single, intravenous
dose: 300 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
HYDROQUINIDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
150 mg 3 times / day multiple, oral
Studied dose
Dose: 150 mg, 3 times / day
Route: oral
Route: multiple
Dose: 150 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Nausea, Epigastric pain...
AEs leading to
discontinuation/dose reduction:
Nausea (25%)
Epigastric pain (25%)
Sources:
738 mg 1 times / day multiple, oral
Studied dose
Dose: 738 mg, 1 times / day
Route: oral
Route: multiple
Dose: 738 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Disc. AE: Gastrointestinal disorder, Photophobia...
AEs leading to
discontinuation/dose reduction:
Gastrointestinal disorder (20%)
Photophobia (4%)
Photosensitivity (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Epigastric pain 25%
Disc. AE
150 mg 3 times / day multiple, oral
Studied dose
Dose: 150 mg, 3 times / day
Route: oral
Route: multiple
Dose: 150 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Nausea 25%
Disc. AE
150 mg 3 times / day multiple, oral
Studied dose
Dose: 150 mg, 3 times / day
Route: oral
Route: multiple
Dose: 150 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Photosensitivity 2%
Disc. AE
738 mg 1 times / day multiple, oral
Studied dose
Dose: 738 mg, 1 times / day
Route: oral
Route: multiple
Dose: 738 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Gastrointestinal disorder 20%
Disc. AE
738 mg 1 times / day multiple, oral
Studied dose
Dose: 738 mg, 1 times / day
Route: oral
Route: multiple
Dose: 738 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
Photophobia 4%
Disc. AE
738 mg 1 times / day multiple, oral
Studied dose
Dose: 738 mg, 1 times / day
Route: oral
Route: multiple
Dose: 738 mg, 1 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
[Hepatitis caused by quinidine. Study of a case and review of the literature].
1986 Mar
Safety and effectiveness of oral quinidine in cardioversion of persistent atrial fibrillation.
2001 Dec
[Adverse drug reactions in three older patients, even without changes in medication].
2003 Mar 29
The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids.
2003 Sep 1
The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy.
2014
Patents

Sample Use Guides

500 mg/12 h mg daily
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Recordings were made from acutely dissociated melanotrophs, obtained following the enzymatic treatment and mechanical disruption of the neuro-intermediate lobe of the pituitary gland of the adult male rat
Halfmaximal inhibition of IK(f) at o mV occurred with 23 + 7.8uM hydroquinidine
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:47:52 GMT 2025
Edited
by admin
on Mon Mar 31 18:47:52 GMT 2025
Record UNII
8P68XPY4HG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
(9S)-10,11-DIHYDRO-6'-METHOXYCINCHONAN-9-OL
Preferred Name English
HYDROQUINIDINE
MI   WHO-DD  
Common Name English
Hydroquinidine [WHO-DD]
Common Name English
NSC-757410
Code English
HYDROQUINIDINE [MI]
Common Name English
DIHYDROQUINIDINE
Common Name English
HYDROCONCHININE
Common Name English
Classification Tree Code System Code
WHO-ATC C01BA13
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
Code System Code Type Description
NSC
757410
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
EPA CompTox
DTXSID50862110
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
SMS_ID
100000077599
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
CAS
1435-55-8
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
MERCK INDEX
m6113
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY Merck Index
FDA UNII
8P68XPY4HG
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
PUBCHEM
91503
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
DRUG BANK
DB15300
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
DRUG CENTRAL
889
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
EVMPD
SUB14136MIG
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
WIKIPEDIA
DIHYDROQUINIDINE
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
RXCUI
27220
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY RxNorm
ECHA (EC/EINECS)
215-862-5
Created by admin on Mon Mar 31 18:47:52 GMT 2025 , Edited by admin on Mon Mar 31 18:47:52 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> METABOLITE
URINE
Related Record Type Details
ACTIVE MOIETY